<DOC>
	<DOCNO>NCT02173769</DOCNO>
	<brief_summary>The decrease physical activity due increase dyspnoea time lead steadily worsen condition increase restriction physical functioning key problem COPD patient affect even early stage . Clinical study investigate Spiriva® Striverdi® Respimat® demonstrate marked improvement physical exercise capacity . However , far data daily practice set everyday functioning combination treatment Spiriva® Respimat® plus Striverdi® Respimat® Spiriva® 18 Mikrogramm plus Striverdi® Respimat® patient require treatment 2 long-acting bronchodilator . The objective NIS measure change physical functioning surrogate physical activity exercise capacity COPD patient treatment Spiriva® Respimat® plus Striverdi® Respimat® Spiriva® 18 Mikrogramm plus Striverdi® Respimat® routine daily treatment ( so-called real life set ) .</brief_summary>
	<brief_title>Changes Physical Functioning Patients With COPD During Therapy With Combination Inhalation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion : Female male patient &gt; = 40 year COPD GOLD 2014 B D Treatment Spiriva® Respimat® plus Striverdi® Respimat® Spiriva® 18 Microgramm plus Striverdi® Respimat® acc . Summary Product Characteristics ( SmPC ) , change routine diagnostics treatment Signed informed consent form inclusion noninterventional study ( NIS ) Exclusion criterion : Patients contraindication acc . Summary Product Characteristics ( SmPC ) pregnant breastfeed woman patient take part different noninterventional study ( NIS ) interventional clinical study time enrol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>